Parlux to defend before Nasdaq
This article was originally published in The Rose Sheet
Executive Summary
Parlux Fragrances must present before a Nasdaq panel or face delisting of its securities from the market, company announces. After the firm delayed filing its December report with the Securities and Exchange Commission, Nasdaq asked the firm to present an explanation to the Nasdaq Listing Qualifications Panel. Parlux has delayed filings in the past, including its as-yet-unfiled September report. The company is also facing a class action suit, filed Nov. 8, 2006, that consolidates five previously filed class action complaints from August and September 2006. The suit alleges that Parlux "knowingly made false statements about its revenues and profitability beginning on Feb. 8, 2006," and that the company's directors sold company shares "while allegedly in possession of material non-public information." Parlux is currently undergoing investigation by an independent audit committee...
You may also be interested in...
Parlux Looks To Diversify, Eagerly Anticipates Can Can Paris Hilton Launch
Parlux's growth strategy focuses on diversifying its distribution channels and building a portfolio of fragrance brands that offers something for everyone, CEO and Board Chairman Neil Katz indicated in a July 19 interview with "The Rose Sheet.
Parlux gets conditional listing
Nasdaq Listing Qualifications Panel grants Parlux's request for continued listing on the stock market subject to the condition that Parlux files its delayed financials on or before March 31, company states March 12. The firm, which presented before the panel earlier this month, has yet to report fiscal year 2006 Q2 and Q3 results (1"The Rose Sheet" March 5, 2007, In Brief). Nasdaq said it will immediately suspend Parlux from trading on the market and may delist its common stock if the firm misses the deadline. Parlux attributes the delay to an ongoing investigation by its audit committee, noting that the company cannot file its reports until the investigation is complete. The committee is investigating a class action suit alleging Parlux "improperly recognized revenue on sales to related parties and failed to comply with SEC disclosure rules." The firm plans to ask the Nasdaq Listing and Hearing Review Council to weigh in on the panel's March 31 deadline...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”